Margenza (margetuximab-cmkb), in combination with chemotherapy, has been approved in the U.S. to treat adults with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease. The therapy is expected to be launched in the U.S. in March, said the therapy’s developer, MacroGenics. “The approval of MARGENZA is an exciting milestone for MacroGenics and, more importantly, it brings a new treatment option to…
You must be logged in to read/download the full post.
The post Margenza Approved in US for Pretreated HER2-positive Breast Cancer appeared first on BioNewsFeeds.